Ali Zeaiter
Colmenar Viejo, MD 28770, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
Journal: Marine drugs
Published: March 15, 2024
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 06, 2023
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 29, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 13, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Journal: Investigational new drugs
Published: April 20, 2023
A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
Journal: Frontiers in oncology
Published: January 27, 2023
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.
Journal: Cancer chemotherapy and pharmacology
Published: June 13, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: March 30, 2022
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Journal: Cancer medicine
Published: March 30, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 03, 2022
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 24, 2022
Last Updated: 09/26/2026